Paris-based Sofinnova Partners has announced the close of an oversubscribed €333 million life science fund that will invest in early-stage healthcare companies – predominantly in Europe. This is the latest addition to the Sofinnova business which also includes funds for industrial biotech and seed investments in gene and cell therapy companies.
The limited partners of the new fund include endowment funds, insurance companies, pension funds, sovereign funds, corporations and family officers, Sofinnova announced on 17 October.